A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Inclusion Criteria:

1. Has the ability to provide informed consent to participate in the study, inaccordance with applicable regulations.

2. Has an understanding, ability, and willingness to comply with Study procedures andrestrictions.

3. ≥ 16 years at the time of screening.

4. Has congenital Type 1 VWD with a residual VWF antigen and/or activity <30 IU/dLand/or meets the bleeding event rate inclusion criteria. Other congenital VWDsubtypes may be enrolled with Sponsor approval.

5. Has symptomatic disease as defined by a history of bruising or bleeding events, withan expected minimum of 3 bleeding episodes (including heavy menstrual bleeding) peryear that require treatment to control bleeding symptoms, and/or has recurrent andongoing episodes of heavy menstrual bleeding at the time of enrollment.

Exclusion Criteria:

1. Has a personal history of venous or arterial thrombosis or thromboembolic disease,except for catheter-associated, superficial vein thrombosis events.

2. Has a significant family history of unprovoked thromboembolic events in first degreerelatives.

3. Has a congenital or acquired bleeding disorder other than VWD.

4. Has planned major surgery within the next 6 months.

5. Is pregnant or plans to become pregnant within the next 6 months.

6. Has any concurrent disease, treatment (including ongoing anticoagulation,antiplatelet, or non-steroidal anti-inflammatory drugs), condition, medication, orabnormality in clinical laboratory tests which may impact on the participant'sbleeding symptoms or affect their ability to complete the study, in theInvestigator's opinion.

7. Has received any investigational product within 30 days prior to screening. If theparticipant was enrolled and dosed in Velora Pioneer (study HMB-002-102;NCT06754852), they must have completed their End of Study Visit.